Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest from Adam Zamecnik
Adalvo and CNX Therapeutics have launched the first extended-release formulation of a pregabalin generic in the UK.
Eyeing the lucrative opportunity, three Indian players have launched their generic versions of Boehringer’s anti-diabetes drug Jardiance in their domestic market.
Medicines for Europe’s director general described the directive as detrimental to the industry, patients, and the Commission’s ambitions to bolster the supply of critical medicines in the bloc as part of the Critical Medicines Act.
ANI’s generic division and rare disease business have both led to a boost in net revenue for the past quarter and in forecasts for the coming year.
After receiving an approval for the Neulasta rival in the US in May 2022, Kashiv BioSciences has now added a further North American country with a positive nod from Canada’s health agency.
After a successful 2024, Hikma has announced plans to ramp up spending on R&D as part of its ongoing turn towards more complex compounds.